Fibrocell Science (FCSC), an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin, connective tissues, and joints.
FCSC’s gene-therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, which is in pre-clinical development stage for the treatment of linear scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.
FCSC has a collaboration agreement with Intrexon Corporation (XON)for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints.
The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009; was incorporated in 1992 and is based in Exton, Pennsylvania.
April 12, 2018
RegMed Investors’ (RMi) closing bell; the force was with the sector
April 11, 2018
RegMed Investors’ (RMi) closing bell; sector pricing withers
April 10, 2018
RegMed Investors’ (RMi) closing bell; chugging along
April 10, 2018
RegMed Investors’ (RMi) pre-open: buckle up
April 9, 2018
RegMed Investors’ (RMi) closing bell; enjoying the high
April 6, 2018
RegMed Investors’ (RMi) closing bell; the newest of new lows
April 4, 2018
RegMed Investors’ (RMi) closing bell; relief rally and a rush to the upside
April 3, 2018
RegMed Investors’ (RMi) closing bell; sector flip-flops through-out the session
April 2, 2018
RegMed Investors’ (RMi) closing bell; sector is technically broken
March 29, 2018
RegMed Investors’ (RMi) closing bell; an overdue rally
35 companies, 1 interpreter!
Insight, foresight and recommendation
Fibrocell Science (FCSC) has always been (to me) a disappointment. January '18 opened at $0.69, rolled barely up and slightly down to open 2/1 at $0.66 and sliding into second base at $0.67 on 2/16 ...Still early with a submission of an IND Application with the U.S. FDA for FCX-013, the Company’s gene therapy candidate for the treatment of moderate to severe localized scleroderma.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors